Senate Hearing on Advances and Funding Needs in Type 1 Diabetes Research

Context & Purpose of the Session

• Meeting takes place in the U.S. Senate; audience includes researchers, advocates, families, and legislators.
• Central theme: securing and sustaining federal resources for medical research, specifically for Type 1 diabetes (T1D, often called “juvenile diabetes”).
• Emphasis on human impact over mere “numbers and dollars.” Personal stories from constituents and families are used to motivate legislative action.

Key Legislative Voices & Positions

• Senator Jerry Moran (Kansas)
  • Welcomes attendees; underscores the importance of seeing the real-life impact of disease.
  • States that investing in medical research is “providing hope.”
  • Intends to co-sponsor Senator Collins’ forthcoming bill after first consulting “juvenile diabetes kids from Kansas.”
  • Frames NIH funding and the Special Diabetes Program (SDP) as avenues for delivering tangible improvements in people’s lives.
• Senator Susan Collins (Maine)
  • Has announced intent to introduce new diabetes-related legislation (bill text not yet filed).
  • Long-time bipartisan partner with Senator Jeanne Shaheen (New Hampshire) on diabetes issues.
• Bipartisan undertone: Moran signals “likely support from Kansas” once formalities completed.

Philosophical & Ethical Undercurrents

• Research funding is portrayed as an ethical duty of Congress: to “provide hope” and “make a difference.”
• The conversation frames T1D research as a societal investment with moral as well as economic returns.

Expert Testimony – Dr. Rogers (NIH/NIDDK, Tenure since $2007$)

Question Posed

• Senator Moran asks: “What are the most impactful advances during your tenure, and what does the future look like?”

Major Scientific Advances Highlighted

1. Disease-Delaying Therapeutics

   • First FDA-approved drug capable of preventing clinical onset of T1D by ≈ $3$ years in a “substantial” patient subset.
   • Pipeline includes “a series of other drugs” to be tested alone or in combination; goal: equal or superior efficacy/safety.

2. Cellular (Biological) Therapies

   • Pursuit of a biological cure: transplant or regenerate insulin-producing β-cells.
   • Pluripotent stem cell strategy:
     • Use a patient’s own stem cells → differentiate into β-cells.
     • Encapsulation technology prevents autoimmune antibody attack while still allowing insulin release.
     • Collaboration with chemical engineers to scale and perfect encapsulation materials.

3. TEDDY Study (The Environmental Determinants of Diabetes in the Young)

   • Longitudinal cohort: $8{,}000$ children at genetic or familial risk.
   • Biobank size: ≈ $5{,}000{,}000$ biological samples (blood, serum, etc.) donated by children and parents.
   • Early findings:
     • Identification of serum protein signatures that predict clinical T1D months in advance.
     • Allows early enrollment of high-risk children into prevention trials.

4. Adapting Oncology Tools: CAR T Cell Therapy

   • CAR T (Chimeric Antigen Receptor T) cells, successful in certain cancers, are repurposed to:
     • Suppress or re-educate autoreactive immune cells.
     • Protect both endogenous and transplanted β-cells from autoimmune destruction.
   • Clinical or pre-clinical studies forthcoming; Dr. Rogers hopes to deliver results within 2–4 years.

Future Outlook (2- to 4-Year Horizon)

• Continued expansion of combination immunotherapies.
• Advancement of stem-cell encapsulation to clinical trials.
• Additional predictive biomarkers from TEDDY data enabling precision-prevention.
• Potential early-stage CAR T trials in T1D.

Funding Acknowledgment

• Dr. Rogers explicitly credits the Special Diabetes Program (SDP) for enabling nearly all enumerated advances.

Cross-Disciplinary Synergies

• Oncology → Immunology → Endocrinology: CAR T technology exemplifies the transfer of knowledge between disease areas.
• Chemical engineering contributions vital for device/encapsulation design.

Real-World & Personal Relevance

• Senators link advances directly to constituents—children in Kansas or Maine—who may benefit from upcoming therapies.
• Delay of disease onset by even $3$ years is framed as transformational for childhood quality of life and family planning.

Practical & Policy Implications

• Sustained or increased NIH & SDP funding is necessary to:
  1. Translate laboratory breakthroughs into approved therapies.
  2. Maintain longitudinal cohort studies (e.g., TEDDY) that generate predictive biomarkers.
  3. Scale complex cellular or gene therapies for broad patient access.
• Legislative action (upcoming Collins/Shaheen bill) aims to lock in these resources.

Numerical & Statistical Highlights (LaTeX-formatted)

• FDA-approved preventive drug delays onset by $\approx 3\ \text{years}$.
• TEDDY cohort size: $8{,}000$ children.
• Biobank: $5{,}000{,}000$ samples collected.
• Dr. Rogers’ tenure: $2007 \text{– present}$.

Meeting Close

• Senator Moran expresses optimism, referencing success of CAR T in cancer as precedent.
• Mutual thanks exchanged among senators and Dr. Rogers.
• Overarching message: bipartisan commitment to “hope” through science, with concrete legislative and research steps forthcoming.